Logo

KIF6

Knowledge of KIF6 Mutation Status Increases Patients' Statin Adherence, Medco Study Finds
Premium

Originally published March 27. By Turna Ray

Celera Will Add to Quest's MDx Capabilities; But Reimbursement Questions Cloud Revenue Contribution
Premium

While Celera can potentially add to Quest's biomarker discovery capabilities and cardiovascular disease testing pipeline, private payors are still not reimbursing for a large share of Celera's products, which may impact how quickly Quest can see a return on its investment.

UCSF Licenses Heart Gene IP from Celera

UCSF will use Celera's KIF6 genetic variant discoveries to develop a test for cardiovascular risk and statin benefit.

Celera and Medco Partner on Statin Drug PGx

Medco wants to know if a gene variant test could predict patient adherence to statin treatment.

Wisconsin Hospitals to Offer Celera's Cardiovascular Genetic Test

Milwaukee-based Aurora Health Care will use Celera's KIF6 test in its heart health programs.
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.